布地奈德、异丙托溴胺及沙丁胺醇三联联合雾化吸入治疗小儿支原体肺炎的临床探讨

clinical investigation on budesonide, ip ratropium bromide amine and albuterol triple combination atomization inhalation to treat pediatric mycoplasma pneumonia

目的探讨布地奈德、异丙托溴胺及沙丁胺醇三联联合雾化吸入在小儿支原体肺炎临床应用的疗效。方法将小儿支原体肺炎80例随机分为治疗组40例和对照组40例。两组均给予规范基础治疗,治疗组加用布地奈德、异丙托溴胺及沙丁胺醇三联联合雾化吸入。结果治疗组从治疗后第2天开始咳嗽症状比治疗前明显减轻,与对照组同期相比差异有显著性。治疗后第八天胸片显示炎性渗出液吸收明显,患者接受度高,与对照组同期相比差异有显著性。结论布地奈德、异丙托溴胺及沙丁胺醇三联联合雾化吸入治疗小儿支原体肺炎能够缓解咳嗽的临床症状,提高患儿患的生活质量。

OBJECTIVE To investigate the curative effect of budesonide, ipratropium bromide amine and albuterol triple combination atomization inhalation on pediatric mycoplasma pneumonia. METHODS 80 infants with mycoplasma pneumonia in pediatric were divided into 2 groups randomly： treatment group（n=40） and control group（n=40）. Two groups were given all standard the treatment group was given with budesonide, ipratropium bromide amine and albuterol triple joint atomization inhalation . RESULTS The cough symptoms in the treatment group began to decrease significantly from the second day after treatment compared with pretherapy. X-ray film of the chest showed the inflammatory exudate absorpted obviously on the eighth day after therapy, the therapeutic regimen were easily accepted by patients, there were significant differences compared with the control group during the same period. CONCLUSION Budesonide, ipratropium bromide amine and albuterol triple combination atomization inhalation to treat pediatric mycoplasma pneumonia can alleviate patient＇s clinical symptoms and improve the quality of life during the illness.